FrieslandCampina Domo and US-based Glycosyn are combining their expertise into a global partnership to develop new infant nutrition ingredients. The parties signed a technology and partnership agreement. Glycosyn has developed a patented technology for the production of oligosaccharides from lactose. FrieslandCampina Domo will produce and introduce these new ingredients onto the global market.
John R. Garrett, co-CEO, at Glycosyn: “Human Milk Oligosaccharides (HMO’s) are specialised carbohydrates which are naturally prevalent in mother’s milk. Through our expertise and know-how we have developed technologies which will complement FrieslandCampina’s extensive history and knowledge of infant nutrition ingredients, products and markets.”
Growing global demand
Tine Snels, Executive Director of FrieslandCampina Ingredients: “Glycosyn helps us to take a very exciting step towards developing the next generation of infant nutrition and to strengthen our position as a market leader in infant nutrition ingredients. We are doing this to meet the growing global demand for high-quality ingredients. Our cooperation is a perfect example of co-creation. The first quantities for trials will be available in the current year.”
Tine Snels, Executive Director of FrieslandCampina Ingredients and Howard M. Newburg, co-CEO, at Glycosyn (r)
FrieslandCampina Domo is part of FrieslandCampina Ingredients and a leading worldwide producer of a wide range of high-quality ingredients for the infant-, medical- and cell nutrition markets. Its range of products consists of whey protein concentrates, demineralised whey products, galacto-oligosaccharides, lactose, hydrolysates, encapsulated nutritional oils and the emerging products which are being developed from the Glycosyn partnership.